United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Sector average
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Scinai Immunotherapeutics Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | 172.7% | 111.74% | 55.78% | 40.25% | 31.58% | 26.06% |
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -35.66% | -65.78% | -93.4% | -102.1% | -108.21% | -114.69% |
| Gross Margin | -202.29% | -202.29% | -202.29% | -202.29% | -202.29% | -202.29% |
| Sector average | 41.94% | 43.27% | 43.22% | |||
| Net Margin | -633.64% | -723.04% | -690.09% | -679.64% | -678.04% | -698.69% |
| Total Assets | $23,292.00K | $13,740.72K | $14,400.22K | $15,338.98K | $16,067.17K | $16,493.36K |
| Sector average | $3,280,499.23K | $3,298,345.31K | $3,676,894.01K | |||
| Net Income | -$8,307.00K | -$12,179.20K | -$13,142.21K | -$15,182.42K | -$16,992.21K | -$18,671.98K |
| 41.95% |
| 40.97% |
| 40.09% |
| $4,262,561.28K |
| $4,994,412.92K |
| $5,761,557.24K |